Pharmacological validation of a translational model of cocaine use disorder: Effects of d-amphetamine maintenance on choice between intravenous cocaine and a nondrug alternative in humans and rhesus monkeys.
Pharmacological validation of a translational model of cocaine use disorder: Effects of d-amphetamine maintenance on choice between intravenous cocaine and a nondrug alternative in humans and rhesus monkeys.
复制标题
可卡因使用障碍转化模型的药理学验证：d-苯丙胺维持对人类和恒河猴静脉注射可卡因和非药物替代品选择的影响。
DOI：
10.1037/pha0000302
复制
发表时间：
2020
影响因子：
2.3
通讯作者：
Negus,SStevens
中科院分区：
文献类型：
--
作者：
Lile,JoshuaA;Johnson,AmyR;Banks,MatthewL;Hatton,KevinW;Hays,LonR;Nicholson,KatherineL;Poklis,JustinL;Rayapati,AbnerO;Rush,CraigR;Stoops,WilliamW;Negus,SStevens
自我给药程序是研究药物使用障碍机制和评价候选药物的实验室研究的金标准。然而，由于缺乏协调，临床前到临床的翻译受到阻碍。为了解决这一限制，我们以前开发了同源静脉内（IV）可卡因选择自我管理程序在恒河猴和人类，然后证明其功能等效。目前的研究试图确定这些程序的敏感性，以d-苯丙胺的维护。3只（N= 3）有可卡因自我给药史的恒河猴和16名（N= 16）患有可卡因使用障碍的人完成了研究。猴维持IV d-苯丙胺（0、0.019、0.037和0.074 mg/kg/h），然后在每种条件下完成7个阶段，其中它们完成9个选择试验，以接受0.14 mg/kg/注射IV可卡因（相当于人体中的10 mg/70 kg）或10个独立的并行渐进比例方案下的食物颗粒。人类维持口服缓释d-苯丙胺（0、30和60 mg/天，对应于猴子中的最低3个剂量），并参加了12个阶段，其中他们选择金钱（6.00美元）或IV可卡因（0、3、10和30 mg/70 kg）。采集血样以比较不同物种间的d-苯丙胺血浆水平。在猴子和人类中，d-安非他明减少了可卡因的选择数量，并在相同的每日剂量下产生了相似的血液水平。d-安非他明在减少猴子对等效可卡因剂量的选择方面与人类相似，但效力较低。这些协调的研究支持这些程序作为可卡因使用障碍的翻译模型的效用。（PsycInfo数据库记录（c）2020阿帕，保留所有权利）
Drug self-administration procedures are the gold standard for laboratory research to study mechanisms of drug use disorders and evaluate candidate medications. However, preclinical-to-clinical translation has been hampered by a lack of coordination. To address this limitation, we previously developed homologous intravenous (IV) cocaine choice self-administration procedures in rhesus monkeys and humans, and then demonstrated their functional equivalence. The present studies sought to determine the sensitivity of these procedures to d-amphetamine maintenance. Three (N= 3) rhesus monkeys with histories of cocaine self-administration and 16 (N= 16) humans with cocaine use disorder completed the studies. Monkeys were maintained on IV d-amphetamine (0, 0.019, 0.037 and 0.074 mg/kg/h), and then completed 7 sessions during each condition in which they completed 9 choice trials to receive 0.14 mg/kg/injection IV cocaine (corresponding to 10 mg/70 kg in humans) or 10 food pellets under independent, concurrent progressive-ratio schedules. Humans were maintained on oral extended release d-amphetamine (0, 30 and 60 mg/day, corresponding to the lowest 3 doses in monkeys) and participated in 12 sessions in which they chose money ($6.00) or IV cocaine (0, 3, 10 and 30 mg/70 kg). Blood samples were taken to compare d-amphetamine plasma levels across species. In monkeys and humans, d-amphetamine reduced the number of cocaine choices and produced comparable blood levels at equivalent daily doses. d-Amphetamine had similar efficacy, though lower potency, at reducing choice for an equivalent cocaine dose in monkeys relative to humans. These coordinated studies support the utility of these procedures as a translational model for cocaine use disorder.(PsycInfo Database Record (c) 2020 APA, all rights reserved)